News
NKTR
1.570
-5.99%
-0.100
Weekly Report: what happened at NKTR last week (0408-0412)?
Weekly Report · 19h ago
NKTR, VERU and EGIO among mid-day movers
U.S. Economy NKTR, VERU and EGIO among mid-day movers. Rent the Runway (RENT) and Rallybio Corp are among the gainers. Aptevo Therapeutics (NA) is one of the biggest losers.
Seeking Alpha · 4d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Rallybio (NASDAQ:RLYB) shares moved upwards by 70.5% to $2.78 during Thursday's regular session. Nektar Therapeutics and Alpine Immune Sciences were the biggest gainers during the session. Akanda and Candel Therapeutic were among the losers.
Benzinga · 4d ago
Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test
Seeking Alpha · 6d ago
Weekly Report: what happened at NKTR last week (0401-0405)?
Weekly Report · 04/08 09:24
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
NASDAQ · 04/03 15:30
Weekly Report: what happened at NKTR last week (0318-0322)?
Weekly Report · 03/25 09:25
Weekly Report: what happened at NKTR last week (0311-0315)?
Weekly Report · 03/18 09:24
Weekly Report: what happened at NKTR last week (0304-0308)?
Weekly Report · 03/11 09:24
Nektar Therapeutics Is Worried About This – Should You Be Worried Too?
TipRanks · 03/07 06:00
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
NASDAQ · 03/06 17:33
Nektar Therapeutics Is Maintained at Hold by Jefferies
Dow Jones · 03/06 14:54
Nektar Therapeutics Price Target Raised to $1.00/Share From $0.50 by Jefferies
Dow Jones · 03/06 14:54
Jefferies Maintains Hold on Nektar Therapeutics, Raises Price Target to $1
Benzinga · 03/06 14:44
U.S. RESEARCH ROUNDUP-Arrivent Biopharma, Ferguson, Target
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Arrivent Biopharma, Ferguson and Target among companies with revised targets. Ferguson, Target and Box are among the companies with new analyst coverage. Analysts raised their ratings on Arrivent, Ferguson, and Target.
Reuters · 03/06 06:47
Nektar Therapeutics reports results for the quarter ended in December - Earnings Summary
Nektar Therapeutics reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 22 cents per share. Revenue rose 8.5% to $23.89 million from a year ago. Nektar shares had risen by 59.3% this quarter.
Reuters · 03/05 23:30
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
NASDAQ · 03/05 15:07
Nektar Therapeutics Q4 2023 GAAP EPS $(0.22) Beats $(0.23) Estimate, Sales $23.89M Beat $18.05M Estimate
Nektar Therapeutics reported quarterly losses of $0.22 per share. The company reported quarterly sales of $23.89 million. Nektar also beat the analyst consensus estimate of $18.05 million by 32.29%. The company's quarterly sales were up 8.45 percent over the same period last year.
Benzinga · 03/04 21:24
Nektar Therapeutics Q4 Loss decreases, but misses estimates
NASDAQ · 03/04 21:18
Nektar Therapeutics GAAP EPS of -$0.22 misses by $0.01, revenue of $23.89M beats by $2.52M
Q4 GAAP EPS of -$0.22 misses by $0.01, revenue of $23.89M beats by $2.52M. Nektar Therapeutics shares down 2.62% in after-hours trading. The company's cash and investments are expected to last into 2026.
Seeking Alpha · 03/04 21:17
More
Webull provides a variety of real-time NKTR stock news. You can receive the latest news about Nektar Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About NKTR
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.